Company intelligence / Profile preview
VISEN Pharmaceuticals
Shanghai, Shanghai, Chinavisenpharma.com ↗
- Ownership
- Public · 2561
- Development stage
- Phase 3
01
Overview
VISEN has three main products in its pipeline. Palopegteriparatide (TransCon PTH) is approved in the EU for hypoparathyroidism. Lonapegsomatropin-tcgd is approved in the US for growth hormone deficiency. Navepegritide (TransCon CNP) is in Phase 2/3 trials for achondroplasia.
- Therapeutic areas
- EndocrinologyRare Diseases
- Modalities
- PeptidesHormonesRecombinant polypeptidesSynthetic peptides
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Shanghai Pharmaceuticals Holding (SPH Group)WuXi BiologicsUnited Family HealthcareMedSciAscendis Pharma A/S
04
Financials
- Market cap
- $185.1M
- Total revenue
- $24.1K
- Enterprise value
- $135.8M
Beyond the preview
Go deeper on VISEN Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VISEN Pharmaceuticals.